학술논문
GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilar
Document Type
Article
Author
Source
In: Expert Opinion on Biological Therapy . (Expert Opinion on Biological Therapy, 2023, 23(8):749-758)
Subject
Language
English
ISSN
17447682
14712598
14712598